Sam Brusco, Associate Editor06.07.22
Medtronic released positive real-world data that supported its next-gen MiniMed 780G insulin pump system at the American Diabetes Association (ADA) annual meeting. MiniMed 780G is an advanced hybrid closed-loop system with meal detection tech that automatically adjusts and corrects glucose levels every five minutes.
The system showed improvements in glycemic outcomes that met consensus guideline recommendations of 70% time in range with less user interaction.
Real-world data from Europe and Chile was presented. In Europe, results from 7,346 people using MiniMed 780G with the Guardian 4 CGM sensor showed improved user experience and strong glycemic outcomes. A second evaluation of 674 European users compared results for those using MiniMed 780G with the Guardian 4 sensor who before used Guardian 3—it was found the Guardian 4 sensor reduced SmartGuard exits and fingersticks.
Overall time in rage (TIR) was 72.9%, and GMI was 6.98%. Those with recommended settings achieved the highest TIR (78.8%) and lowest time below range (TBR) (1.8%).
Medtronic also presented data from 37 system users with type 1 diabetes in Chile. Average TIR was 78.4%, average GMI was under 7%, and 77% of study targets had TIR over 70% and GMI under 7%.
Lastly, data from 176 patients who continued using MiniMed 780G with Guardian 4 after the U.S. pivotal trial was shared. At three months with recommended settings, HbA1C was 7.1% overall, TIR was 74.7%, and TBR was 2.1%.
MiniMed 780G is now available in over 40 countries and is being reviewed by the U.S. Food and Drug Administration (FDA) for approval.
The system showed improvements in glycemic outcomes that met consensus guideline recommendations of 70% time in range with less user interaction.
Real-world data from Europe and Chile was presented. In Europe, results from 7,346 people using MiniMed 780G with the Guardian 4 CGM sensor showed improved user experience and strong glycemic outcomes. A second evaluation of 674 European users compared results for those using MiniMed 780G with the Guardian 4 sensor who before used Guardian 3—it was found the Guardian 4 sensor reduced SmartGuard exits and fingersticks.
Overall time in rage (TIR) was 72.9%, and GMI was 6.98%. Those with recommended settings achieved the highest TIR (78.8%) and lowest time below range (TBR) (1.8%).
Medtronic also presented data from 37 system users with type 1 diabetes in Chile. Average TIR was 78.4%, average GMI was under 7%, and 77% of study targets had TIR over 70% and GMI under 7%.
Lastly, data from 176 patients who continued using MiniMed 780G with Guardian 4 after the U.S. pivotal trial was shared. At three months with recommended settings, HbA1C was 7.1% overall, TIR was 74.7%, and TBR was 2.1%.
MiniMed 780G is now available in over 40 countries and is being reviewed by the U.S. Food and Drug Administration (FDA) for approval.